Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V0VI
|
|||
| Former ID |
DIB001795
|
|||
| Drug Name |
11C-AZD-2184
|
|||
| Synonyms |
AZD-2184-[11C]; AZD-2184-[3H]; Tritium-AZD-2184; Beta amyloid modulator (iv PET ligand, AD), AstraZeneca; Carbon-11-AZD-2184; Hydrogen-3-AZD-2184; Beta amyloid modulator (iv PET ligand, Alzheimer's disease), AstraZeneca; 3H-AZD-2184
Click to Show/Hide
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Structure |
 |
Download2D MOL |
||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00838877) Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for A Amyloid. U.S. National Institutes of Health. | |||
| REF 2 | Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.